Quoin Pharmaceuticals, Ltd.
No enriched coverage for $QNRX in the last 7 days.
No SEC Form 4 filings for $QNRX in the last 30 days.
Quoin Pharmaceuticals said the FDA cleared its IND for QRX003 to start a Phase II trial for Peeling Skin Syndrome. The study is expected to begin in 2H 2026, enrolling 6 to 8 patients in the US and Europe. Patients will apply the topical lotion twice daily to over 80% of body surface for 52 weeks. Quoin targets approval in 2028.
Quoin Pharmaceuticals (QNRX) said the FDA cleared its IND for QRX003 in Peeling Skin Syndrome, allowing it to start a planned Phase 2 trial. The study is expected to begin in 2H 2026, enrolling 6-8 patients and dosing twice daily for 52 weeks. The company cited no FDA safety concerns and prior investigator-led pediatric results showing improvements by Week 12.
Quoin Pharmaceuticals (NASDAQ: QNRX) said the FDA cleared its IND for QRX003 to start a Phase 2 study for Peeling Skin Syndrome. The trial is expected to begin in 2H 2026 and enroll 6-8 pediatric and adult patients in the US and Europe. FDA reported no safety concerns on design and dosing duration. Quoin targets approval in 2028.
Recent QNRX coverage spans financial news, regulation and technology.
IND clearance for a new Phase II indication is a tangible de-risking step and can re-rate clinical probability for QRX003 in PSS.
IND clearance de-risks the regulatory path and moves QRX003 into Phase 2 execution, which can improve probability-weighted timelines and sentiment.
IND clearance de-risks early clinical execution for QRX003 in PSS and expands the label pathway beyond Netherton Syndrome.
Japan commercialization infrastructure is being built ahead of a potential QRX003 approval, supporting the company’s self-commercialization plan.
IND submission and Phase 2 timing provide a concrete regulatory/clinical de-risking step for QRX003, potentially improving probability-weighted value.
alphai scores every news story that mentions QNRX with an AI model for sentiment and relevance, and aggregates insider trades from Quoin Pharmaceuticals, Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Quoin Pharmaceuticals said the FDA cleared its IND for QRX003 to start a Phase II trial for Peeling Skin Syndrome. The study is expected to begin in 2H 2026, enrolling 6 to 8 patients in the US and Europe. Patients will apply the topical lotion twice daily to over 80% of body surface for 52 weeks. Quoin targets approval in 2028.
3 min readQuoin Pharmaceuticals (QNRX) said the FDA cleared its IND for QRX003 in Peeling Skin Syndrome, allowing it to start a planned Phase 2 trial. The study is expected to begin in 2H 2026, enrolling 6-8 patients and dosing twice daily for 52 weeks. The company cited no FDA safety concerns and prior investigator-led pediatric results showing improvements by Week 12.
3 min readQuoin Pharmaceuticals (NASDAQ: QNRX) said the FDA cleared its IND for QRX003 to start a Phase 2 study for Peeling Skin Syndrome. The trial is expected to begin in 2H 2026 and enroll 6-8 pediatric and adult patients in the US and Europe. FDA reported no safety concerns on design and dosing duration. Quoin targets approval in 2028.
3 min readQuoin Pharmaceuticals (NASDAQ: QNRX) said it has completed a wholly owned Japan subsidiary to prepare for direct commercialization of QRX003 for Netherton Syndrome, if approved. The move follows Japan’s MHLW granting Orphan Drug Designation to QRX003. QRX003 is in Phase 2; Phase 3 is expected to start H2 2026 with a potential NDA filing in 2027.
2 min readQuoin Pharmaceuticals said it filed an IND with the FDA for QRX003 to treat Peeling Skin Syndrome, based on results from an ongoing investigator-led pediatric study. The company expects to start a Phase 2 trial in the second half of 2026 after FDA review. It reported improvements in skin, sleep and quality of life, and said QRX003 was well tolerated.
4 min readStonepine Capital Management, LLC, a ten percent owner of Quoin Pharmaceuticals, Ltd. (QNRX), has filed a Form 4 with the SEC, indicating no reported purchases, sales, or other share transactions. The filing notes that due to a change in outstanding shares, Stonepine Capital now beneficially owns less than 10% of Quoin Pharmaceuticals' outstanding ordinary shares, despite being classified as a 10% owner on the form. This Form 4 suggests a neutral impact on sentiment as it reports no new trading activity.
2 min readQuoin Pharmaceuticals (NASDAQ: QNRX) announced its Q4 and full-year 2025 financial results and provided a corporate update, highlighting significant progress in its clinical development and regulatory strategies for rare and orphan diseases. The company secured up to $104.5 million in private placement financing, gained Orphan Drug Designations for QRX003 in both the U.S. and Europe, and advanced expedited regulatory pathways in Japan and Saudi Arabia. Quoin also reported continued positive clinical data for QRX003 in Netherton Syndrome, expanded its pediatric and Peeling Skin Syndrome studies, and has plans for further clinical trials and an IND submission for QRX003 later this year, while its topical rapamycin platforms are set for clinical studies in the second half of 2026.
5 min readQuoin Pharmaceuticals announced a private placement of up to $104.5 million, securing orphan and Fast Track designations for its lead drug QRX003, which is aimed at treating Netherton Syndrome. The company also expanded its pediatric study for Netherton Syndrome to seven patients and anticipates initiating Phase 3 and releasing topline data in the second half of 2026. Despite widening net losses in 2025, Quoin's year-end cash balance of $18.7 million is expected to fund operations into 2027.
4 min readQuoin Pharmaceuticals Ltd (QNRX) is expected to announce a loss of $3.34 per share, according to this earnings preview. The information is provided by Refinitiv and Reuters.
2 min readTarget Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively ...
2 min read
